Abstract
Background: Acute myocardial infarction (AMI) is characterized by high mortality and disability rates. Timely and effective revascularization has saved the lives of many patients. However, some patients develop complications such as heart failure (HF) following myocardial infarction, which significantly affects their quality of life and may even be life-threatening. Therefore, the search for effective biomarkers to predict the occurrence of HF after AMI, along with early prevention and treatment strategies, will greatly improve clinical outcomes for patients with post-myocardial infarction HF
Methods: A total of 170 patients with acute myocardial infarction (AMI) were enrolled in this study, including 44 patients with post-AMI heart failure (HF) and 126 patients with post-AMI non-HF. We measured the serum biomarkers NT-proBNP, cTNT, PLR, NLR, and GDF-15 in all patients using enzyme-linked immunosorbent assay (ELISA). Subsequently, we performed t-tests to assess the predictive value of these biomarkers for post-AMI heart failure (HF).
Results: In the group of HF patients, cTNT, NT-proBNP, GDF-15 and NLR was significantly higher than in the group without HF, but PLR was not .The AUC of NLR to predict HF after AMI was 0.632 (95%CI:0.542-0.723), P=0.010, with a cut-off value of (3.86×109)/L , GDF-15 was 0.661 (95%CI0.560-0.763), P=0.002, with a cut-off value of 1.35 ng/mL, and NT-proBNP was 0.82 (95%CI0.723-0.876), P<0.001, with a cut-off value of 1444 pg/mL.
Conclusions: In five biomarkers, there is predictive value in NT-proBNP , NLR, GDF-15 for patients with HF after AMI .
Keywords
Array
Array
Array
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.